Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 20, 2007

Pro-Pharmaceuticals Works with Chemwerth to Scale Up Davanat

  • Pro-Pharmaceuticals is collaborating with Chemwerth to scale up production of its lead drug candidate, Davanat®, to 100 kilograms for initial marketing needs. 

    Davant is a carbohydrate polymer composed of mannose and galactose (galactomannan). Pro-Pharmaceuticals believes  that its mechanism of action is based upon binding to lectins on the cell surface. It thus theorizes that the product targets specific lectin receptors that are over-expressed on cancer cells.

    Current research indicates that Galectins affect cell development and play important roles in cancer, including tumor cell survival, angiogenesis, and tumor metastasis, according to a Pro-Pharmaceuticals. The company hence believes that this form of targeted delivery may allow for higher doses of chemotherapy administration with no increase in toxicity.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »